Although AML with −7 is classified into one ELN adverse-risk group, it should be noted that survival among these clinically poorly performing patients may still differ with a potential survival benefit in IDH2mut patients but at the same time, even poorer outcomes in the presence of TP53 and PTPN11 aberrations. The gene discussed is PTPN11; the disease is acute myeloid leukemia.